Answers are grounded in this paper and cite their sources.
Background Hypertension and cognitive decline interact bidirectionally through the brain-heart axis. This study evaluated the multidomain adaptive computerised cognitive training (CCT) as a digital therapeutic for improving cognition and inducing neural and haemodynamic changes in hypertensive patients with mild cognitive impairment (MCI). Methods This multicentre, double-blind, randomised, active-controlled, clinical trial was conducted at 11 hospitals across six Chinese regions. Eligible participants were adults aged 60 years or older with hypertension, subjective cognitive decline, and a Montreal Cognitive Assessment (MoCA) score of less than 26. Patients were randomly assigned (in blocks of 6) 1:1 to receive 12 weeks of multidomain adaptive CCT (MD-CCT) or fixed-domain CCT (FD-CCT). At 12-week follow-up, participants assigned to MD-CCT were randomly assigned 1:1 to continue or stop training for another 12 weeks. The primary outcome was global cognitive improvement at 12 weeks. Secondary outcomes included subdomain and psychological changes at 12 and 24 weeks. Exploratory outcomes included neuroimaging measures derived from functional and structural ultra-high-field 7-T MRI, as well as haemodynamic indices of systolic blood pressure, diastolic blood pressure, heart rate, and rate-pressure product. This trial is registered at ClinicalTrials.gov, NCT05704270, and is complete. Findings Between March 8 and Oct 13, 2023, 217 participants were enrolled (MD-CCT n=108; FD-CCT n=109). At week 12, no significant between-group difference emerged in multidomain cognitive improvement (13% [13 of 101] vs 17% [17 of 103]; adjusted odds ratio 0·59, 95% CI 0·25–1·36; p=0·21). Both groups showed within-group gains in MoCA and working memory (p FDR s <0·026), although only the MD-CCT group had improved processing speed (p FDR = 0·041). The MD-CCT group showed enhanced functional connectivity in attention, executive control, and episodic memory networks (p FDR s <0·043), and increased grey matter density in hippocampus (p FDR = 0·040), along with greater reduction in diastolic blood pressure, heart rate and rate-pressure product (p FDR s <0·022) relative to FD-CCT. Alterations in functional connectivity mediated the intervention effect on general cognition (indirect effects ranging from 0·71 to 1·17; p FDR s <0·038) and were also negatively associated with reductions in heart rate (p FDR s <0·045). At 24-week follow-up, no significant difference in multidomain cognitive improvement proportion emerged between the MD-keep and MD-stop groups (10% [5 of 48] vs 19% [10 of 53], p FDR = 0·675). Both subgroups showed greater diastolic blood pressure reduction than the FD-CCT group (p FDR s <0·017). Interpretation The MD-CCT did not differ significantly from FD-CCT in cognitive improvement, but uniquely benefited neural and haemodynamic outcomes, supporting its potential as an integrated digital therapeutic for hypertension with cognitive impairment.
No takes yet. Share an insight, caveat, or question.
Kong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: